Cell Therapy News/Articles, page-17297

“His research program focused on allogeneic hematopoietic cell transplantation with an emphasis on improving outcomes for patients with graft-versus-host disease (GVHD). The centerpiece of Dr. Levine’s research is the MAGIC program, a collaborative effort among over 20 centers in North America, Europe, and Asia, that prospectively studies adult and pediatric recipients of an allogeneic HCT and contains the world’s largest data collection and biorepository dedicated to understanding the biology and clinical course of GVHD. Dr. Levine led the MAGIC effort that created the new international standard for clinical GVHD staging and grading and together with his laboratory collaborator, Dr. James Ferrara, they invented a biomarker blood test that accurately predicts outcomes for patients who require treatment for GVHD. This work has since been translated into clinical trials that test risk-adapted treatments to improve responses and decrease toxicity of GVHD therapy.”

Interesting CV of Dr. John Levine, Chair-Elect of the Steering Committee of the Bone Marrow & Transplant Clinical Trials NetworkL

https://profiles.mountsinai.org/john-e-levine